PT  - JOURNAL ARTICLE
AU  - Carazo, Sara
AU  - Guay, Charles-Antoine
AU  - Skowronski, Danuta M
AU  - Amini, Rachid
AU  - Charest, Hugues
AU  - De Serres, Gaston
AU  - Gilca, Rodica
TI  - Influenza hospitalization burden by subtype, age, comorbidity and vaccination status: 2012/13 to 2018/19 seasons, Quebec, Canada
AID  - 10.1101/2023.08.04.23293392
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.04.23293392
4099  - http://medrxiv.org/content/early/2023/08/08/2023.08.04.23293392.short
4100  - http://medrxiv.org/content/early/2023/08/08/2023.08.04.23293392.full
AB  - Background The primary objective of influenza immunization programs is to reduce the risk and burden of severe outcomes. To inform optimal program strategies, we monitored influenza hospitalizations over several seasons of varying subtype predominance, stratified by age, comorbidity and vaccination status.Methods We assembled data from an active hospital-based surveillance network involving systematic swabbing and PCR-confirmation of influenza virus infection by type/subtype during peak-weeks of seven influenza seasons (2012/13 to 2018/19) in Quebec, Canada. We estimated seasonal, population-based incidence of influenza-associated hospitalizations (interpreted as risk) by subtype, age, comorbidity and vaccine status, and derived the number-needed-to-vaccinate to prevent one hospitalization per stratum.Results The average seasonal incidence of influenza-associated hospitalization was 89/100,000 (95%CI: 86, 93), lower during A(H1N1) (49-82/100,000) than A(H3N2) seasons (73-143/100,000). Overall risk followed a J-shaped age pattern, highest among infants 0-5 months and adults ≥75 years. Hospitalization risks were highest for children <5 years during A(H1N1) but for adults ≥75 years during A(H3N2) subtype- predominant seasons. Age-adjusted hospitalization risks were 7-fold higher among individuals with versus without comorbidities (214 versus 30/100,000). The number-needed-to-vaccinate to prevent hospitalization was 82-fold lower for ≥75-years-olds with comorbidity (n=1,995), who comprised 39% of all hospitalizations, than for healthy 18-64-year-olds (n=163,488), who comprised just 6% of all hospitalizations.Conclusions In the context of broad-based influenza immunization programs (targeted or universal), severe outcome risks should be simultaneously examined by subtype, age, comorbidity, and vaccine status. Policymakers require such detail to prioritize further promotional efforts and expenditures toward the greatest and most efficient program impact.40-word summary This hospital-based study involving systematic PCR testing over seven seasons revealed important differences in influenza hospitalization risk by subtype, age, comorbidity, and vaccination status. The findings highlight the need for data-driven decision-making to optimize vaccination strategies and minimize healthcare burden.Competing Interest StatementSC, RA and RG report funding from the Ministère de la santé et des services sociaux du Québec to conduct this work, paid to their institution. DS reports funding from Public Health Agency of Canada and British Columbia Center for Diseases Control Foundation for Public Health for influenza and COVID-19 studies but not pertaining to the current study; from Michael Smith Foundation for Health Research and from Canadian Institutes of Health Research for COVID-19 studies but not pertaining to the current study; all grants were paid to her institution. All other authors report no potential conflicts.Funding StatementThis work was supported by the Ministère de la santé et des services sociaux du QuébecAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For the first three years, participating hospitals each obtained Institutional Review Board approval from Comité d éthique de la recherche du Centre hospitalier de l Université Laval, from Comité d éthique de la recherche du Centre de santé et des services sociaux de Chicoutimi, from Comité scientifique et d éthique de la recherche du Centre de santé et de services sociaux de Laval, from Comité central d éthique de la recherche du ministre de la Santé et des Services sociaux du Centre de santé et de services sociaux du Haut-Richelieu et Centre de santé et de services sociaux de Rimouski-Neigette. Thereafter, activities were incorporated into routine provincial surveillance, mandated by the Ministry of Health, and a waiver was obtained from the Research Ethics Board of the Centre hospitalier universitaire de Québec-Université Laval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual data not publicly available